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Abstract  
 
Maternal obesity is the most common metabolic disturbance in pregnancy affecting more 
than 1 in 5 women in some countries. Babies born to obese women are heavier with more 
adiposity at birth, and are vulnerable to obesity and metabolic disease across the lifespan 
suggesting offspring health is ‘programmed’ by fetal exposure to an obese intra-uterine 
environment. The placenta plays a major role in dictating the impact of maternal health on 
prenatal development. Maternal obesity impacts the function of integral placental receptors 
and transporters for glucocorticoids and nutrients, key drivers of fetal growth, though 
mechanisms remain poorly understood. This review aims to summarise current knowledge 
in this area, and considers the impact of obesity on the epigenetic machinery of the 
placenta at this vital juncture in offspring development. Further research is required to 
advance understanding of these areas in the hope that the trans-generational cycle of 
obesity can be alleviated.  
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Introduction 
 
Obesity is one of the greatest public health challenges of the 21st century. Since 1980, the 
prevalence of obesity (body mass index [BMI] ≥ 30kg/m2) has doubled in more than seventy 
countries and has steadily increased in most other countries, across the range of 
socioeconomic development [1]. In 2016, over 650 million adults were estimated to be 
obese, representing approximately 13% of the world’s adult population. At this time, over 
340 million children and adolescents aged 5 to 19 years were estimated to be overweight or 
obese, a prevalence of 18% in this age group [2]. In this context, it is unsurprising that rates 
of maternal obesity are also rising. Estimates of the prevalence of pre-pregnancy obesity 
across Europe in 2010 ranged from 7.1% in Poland to 20.7% in Scotland [3]. In 2011-12, the 
prevalence of obesity in women age 20-39 years in the United States was approximately 
31.8% [4].  
 
Obesity during pregnancy is an important risk factor for adverse health outcomes in the 
mother and offspring. Obese women have an increased risk of pregnancy complications 
compared to normal weight women including gestational diabetes mellitus, gestational 
hypertension, pre-eclampsia, caesarean section, postpartum haemorrhage and stillbirth 
[5,6]. Adverse phenotypes in the offspring are evident in the neonatal setting, with babies 
born to obese mothers demonstrating greater adiposity and increased umbilical cord blood 
insulin and inflammatory cytokine levels compared to babies born to lean mothers [7]. 
Maternal BMI correlates positively with birthweight and the offspring are typically born 
heavier than those born to lean women [8,9]. Maternal obesity is associated with an 
elevated offspring risk of metabolic and cardiovascular disease in child- and adulthood 
including obesity, type 2 diabetes mellitus, coronary heart disease, stroke and 
cardiovascular disease [10–12]. The offspring of obese women also have an elevated risk of 
childhood asthma, type 1 diabetes (in the absence of parental diabetes), and may display 
poorer cognitive performance than those born to lean mothers [13–16]. Intrauterine growth 
restriction (IUGR) is less common in the context of maternal obesity, occurring in 
approximately 5 to 7% of pregnancies, and may relate to placental vascular dysfunction, for 
example in the context of pre-eclampsia [17,18]. Offspring who fail to reach their genetically 
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determined growth potential in-utero display increased growth velocity during childhood 
but remain shorter and lighter than their normal counterparts aged 9 years and have an 
increased risk of short and long-term adverse health outcomes [19,20].  
 
The relationship between maternal health and fetal development is closely mediated by the 
placenta, which controls many aspects of the intra-uterine environment including oxygen 
delivery, nutrient transport and hormone production and transfer to the developing fetus. 
The placenta therefore plays a key role in developmental ‘programming’, the phenomenon 
whereby early life development determines susceptibility to disease in adulthood [21]. 
Mechanistic studies demonstrate that maternal obesity is associated with changes in 
placental function and structure which likely impact on fetal growth and development. For 
example, increased gene expression of the chemotactic cytokines interleukin (IL) 1β, IL 8 
and monocyte chemoattractant protein-1 (MCP-1) and increased macrophage infiltration 
are evident in the placenta of obese women, suggesting an exaggeration of the 
inflammatory state which occurs in normal pregnancy [22,23]. Studies of placental histology 
indicate obesity is associated with hyperplasia of the muscular tissue of the tunica media in 
placental vessel walls and immaturity of the placental villous tree, as evidenced by fewer 
villi of larger diameter and with abnormal angiogenesis [22,24].  
 
Alterations in placental nutrient and hormone transporter capacity have been 
demonstrated in human and animal models of obesity and are hypothesised as a 
mechanism leading to an accelerated fetal growth trajectory and macrosomia [25,26]. The 
Pedersen hypothesis, postulated in the 1920’s, stated that maternal hyperglycaemia leads 
to fetal hyperglycaemia, fetal islet cell hypertrophy and fetal insulin hypersecretion. 
However, it has since been recognised that when present in excess, other macronutrients 
such as fatty acids and amino acids may behave as insulin secretagogues and contribute to 
accelerated fetal growth [27]. It is also now recognised that glucocorticoids are vitally 
important for fetal growth and that circulating cortisol levels are influenced by maternal 
obesity [28,29]. Placental handling of glucocorticoids therefore presenting a potential 
mechanism through which maternal obesity influences fetal development in-utero. 
Furthermore, the potential role of epigenetic processes during pregnancy to adversely 
programme the health of offspring has received increasing attention and is important to 
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consider. This review will focus on the impact of maternal obesity on placental 
glucocorticoid and macronutrient transfer and epigenetic processes, considering the 
mechanisms which may influence maternal and fetal health in this setting. 
 
Glucocorticoids  
  
Glucocorticoids in fetal development 
 
Glucocorticoids are essential for fetal growth, maturation and survival, and are transported 
from the maternal to the fetal circulation via placental syncytiotrophoblasts. In-utero 
glucocorticoid exposure, which is dependent on the activity of the maternal hypothalamic-
pituitary-adrenal (HPA) axis and placental glucocorticoid transfer, has a crucial impact on 
both fetal development and, potentially, life-long health [28]. In humans, levels of the major 
circulating glucocorticoid cortisol are under regulation of the HPA axis, which undergoes 
dramatic activation in pregnancy. During the second and third trimesters, the placenta 
secretes high levels of corticotrophin-releasing hormone into the maternal circulation, 
promoting release of adrenocorticotrophic hormone (ACTH) and cortisol from the anterior 
pituitary and adrenal glands respectively [30]. Rising cortisol levels in the maternal 
circulation stimulate further corticotrophin-releasing hormone release from the placenta, 
resulting in a positive feedback loop [31]. Additionally, the high oestrogen state of 
pregnancy promotes increased hepatic production of cortisol binding globulin (CBG). CBG is 
the principal plasma binding protein for cortisol, and in order to maintain the proportion of 
bound versus unbound cortisol, there is an associated increase in serum levels of free, or 
active, cortisol [30]. As a consequence of these mechanisms, there is a three-fold increase in 
total serum levels of cortisol, between the first and third trimesters [32]. The fetal adrenal 
glands produce cortisol transiently from approximately 7 to 10 weeks gestation, with 
progressively increasing production occurring during the third trimester [33]. 
 
Studies of the HPA axis in obese pregnant women show that total cortisol levels are lower 
throughout pregnancy than in lean women [29]. HPA axis activity appears blunted in these 
women with a lack of rise of corticotrophin-releasing hormone and cortisol binding globulin 
and a reduction in the pulse frequency of cortisol secretion [29,34]. This failure of the 
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maternal HPA axis to activate as observed in lean pregnant women, results in lower than 
normal fetal glucocorticoid exposure, and has been postulated as a factor contributing to 
macrosomia and later gestation at delivery in severely obese women [29,35]. Conversely, 
over-exposure to glucocorticoids in-utero is associated with intrauterine growth restriction, 
shorter gestation at delivery, and increased risk of cardiometabolic disease and psychiatric 
disease in adulthood [28,36,37].  
 
Placental glucocorticoid receptors and transporters 
 
Fetal exposure to glucocorticoids is mediated by a range of key placental receptors and 
transporters (Figure 1). Glucocorticoids elicit most of their effects through the 
glucocorticoid receptor (GR) and mineralocorticoid receptor (MR). These intracellular, 
structurally similar receptors are members of a superfamily of ligand-dependent 
transcription factors [38]. The GR is ubiquitously expressed throughout the body and 
encoded by the gene NR3C1 (nuclear receptor subfamily 3, group C, member 1) on 
chromosome 5 [39]. In-utero, GR expression is evident in most fetal tissues from mid-
gestation onwards, and is highly expressed in the placenta and fetal membranes [40]. The 
human placenta possesses at least eight isoforms of GR: GRα-A, GRβ, GRα-C, GRP, GRA, 
GRα-D1, GRα-D2 and GRα-D3 [41]. Differential expression of GR isoforms have been 
suggested to influence placental glucocorticoid sensitivity and fetal growth. For example, 
GRβ and GRα-D1 expression were significantly higher in term placentae associated with a 
small for gestational age fetus [41]. The MR is coded for by the NR3C2 gene (nuclear 
receptor subfamily 3, group C, member 2) on chromosome 4 and is expressed in the 
syncytiotrophoblast, cytotrophoblast and interstitial cells of the villous core [42]. Whilst it 
has a similar binding affinity for mineralocorticoids and glucocorticoids, its major role is to 
mediate the effects of the vasoactive hormone aldosterone to control sodium and water 
balance [43]. Aldosterone levels rise during pregnancy and observations that 
adrenalectomized ewes demonstrate reduced placental mass despite cortisol 
supplementation, but not when supplemented with aldosterone, suggest aldosterone plays 
an important role in placental growth [44,45]. The relative density of MR and GR receptors 
in the placenta across gestation is not known. Aldosterone has been suggested to act as a 
growth factor for several tissues including the placenta, renal mesangial cells and cardiac 
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fibroblasts however the mechanism of this effect is uncertain [44,46,47]. Inactivation of 
cortisol by 11β-HSD-2 allows aldosterone to effectively stimulate the MR and limits 
activation of GR. 11β-HSD-2 activity may be altered in association with pregnancy metabolic 
complications, resulting in a change in MR/GR receptor activation. For example, in the 
context of maternal obesity, it is hypothesised that 11β-HSD-2 activity is increased, resulting 
in comparatively less GR and more MR receptor activation.  
  
Another family of membrane proteins, the ATP-binding cassette (ABC) transporters, are 
implicated in the placental regulation of fetal glucocorticoid exposure. These transporters 
efflux a wide variety of compounds against their concentration gradient across intra- and 
extracellular membranes by utilising energy created through ATP hydrolysis [48]. In the 
placenta, several ABC transporters have been identified in the syncytiotrophoblast and fetal 
vessel endothelium (Table 1) [49]. As ABC transporters efflux substrates out of the cell, their 
placement on the opposing microvillous membrane (MVM) and basolateral membrane (BM) 
of the syncytium perhaps provides insight into their physiological roles [49]. Key 
transporters implicated in placental glucocorticoid transfer include permeability 
glycoprotein (encoded by ABCB1), breast cancer resistance protein (encoded by ABCG2) and 
the multidrug resistance associated protein-1 (encoded by ABCC1) [48]. ABCC1 exports 
corticosterone (not cortisol) and is predominantly localised on the fetal facing BM [49,50]. 
Corticosterone circulates at 10-20-fold lower concentrations than cortisol in the human 
plasma, and its physiological role remains uncertain [51]. On the other hand, ABCB1 exports 
cortisol (not corticosterone) and is located on the maternal facing MVM. Thus, these 
membrane transporters likely play a role in fine-tuning fetal glucocorticoid exposure. 
Further investigation is required to clarify the role of ABC transporters, including whether 
this is altered in context of maternal obesity, in regulating placental glucocorticoid 
sensitivity and transfer to the developing fetus. 
 
Throughout the body, glucocorticoid activity is mediated by the action of microsomal 
enzymes which function as pre-receptor signalling pathway modulators. The enzymes 
believed to most crucially regulate maternal-fetal cortisol transfer are the two known 
human isoforms of 11β-hydroxysteroid dehydrogenase (11β-HSD). 11β-HSD-2 is located in 
the syncytiotrophoblast (Figure 2) and converts biologically active maternal cortisol into 
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inactive cortisone. This enzyme acts as a ‘barrier’ to prevent excessive fetal exposure to 
cortisol derived from the activated maternal system [52,53]. It was previously reported that 
placental 11β-HSD-2 inactivates the majority of maternal cortisol, however a recent study 
examining placental glucocorticoid transfer reported that even when 11β-HSD-2 activity was 
inhibited with carbenoxolone, (a potent HSD inhibitor), less than 10% of maternal cortisol 
crossed the placenta. This finding suggests other mechanisms are active in protecting the 
fetus from high maternal cortisol levels [53]. It has been suggested that due to the 
significantly higher cortisol concentrations in the maternal circulation compared to the fetal 
circulation, relatively small changes in 11β-HSD-2 activity may result in clinically significant 
alterations in fetal glucocorticoid exposure [28]. For example, one small study demonstrated 
that a 500nmol/l increase in maternal cortisol concentrations (a 1.5 standard deviation 
change) resulted in a 30nmol/l increase in fetal cortisol concentrations (a 1.1 standard 
deviation change) [54]. In contrast to 11β-HSD-2, 11β-HSD-1 re-activates maternal cortisone 
to cortisol and is located in extravillous trophoblasts, endothelial cells lining blood vessels in 
placental villous tissue and umbilical cord, and fetal membranes, with no presence detected 
in syncytiotrophoblasts [55]. The role of 11β-HSD-1 in determining maternal or fetal cortisol 
exposure is less well described.  
  
Table 1: Human placental ABC transporters (adapted from [49]) 
Transporter Syncytiotrophoblast 
location 
Substrates/function 
ABCA1 Microvillous Cholesterol, phospholipids 
ABCB1 Microvillous Cortisol, drug resistance (antibiotics, antiemetic, 
cardiac drugs, HIV protease inhibitors) 
ABCB4 Basolateral Bile acids 
ABCC1 Basolateral, 
microvillous 
Corticosterone, folate 
ABCC2 Microvillous Folate, bilirubin, role in chemoprotection and 
detoxification 
ABCC3 Microvillous Bilirubin 
ABCC4 Microvillous Conjugated bile acids 
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ABCC5 Basolateral Cyclic nucleotides 
ABCC7 Microvillous Chloride transport 
ABCG1 Basolateral Cholesterol, phospholipids 
ABCG2 Microvillous Drug resistance 
ABC: ATP-binding cassette, HIV: human immunodeficiency virus 
 
Obesity and placental glucocorticoid sensitivity and transfer 
 
The impact of obesity on glucocorticoid sensitivity and transfer is yet to be established. 
However, unpublished data from our group (Reynolds et al., unpublished) suggests that 
placental 11β-HSD-2 messenger ribonucleic acid (mRNA) levels correlate positively with 
maternal BMI and are highest in term samples from obese women with macrosomic 
(>4000g) infants compared to lean women. This exploratory finding raises the possibility 
that an up-regulated placental 11β-HSD-2 barrier is an important mechanism contributing to 
reduced fetoplacental glucocorticoid exposure in obese pregnant women, potentially 
contributing to the prolonged gestation and higher birthweight observed in this population 
[56]. Further research is required to replicate this finding in a larger cohort, and to 
characterise the impact of obesity on the activity and function of placental glucocorticoid 
receptors and ABC transporters during pregnancy.   
 
In addition to obesity, other maternal factors have been shown to regulate placental 
glucocorticoid sensitivity and transfer. For example, low maternal education status was 
associated with increased placental GR and 11β-HSD-1 mRNA expression in a Finnish cohort 
of 67 healthy pregnant women [57]. Abnormal mood is also an important factor, with 
maternal depressive symptoms across pregnancy in a group of 56 lean women shown to 
correlate with increased placental mRNA expression of GR and MR [58]. In a follow-up study 
of this cohort, increased regulatory behavioural challenges in the offspring at mean age 15.6 
days were associated with increased placental expression of GR, 11β-HSD-1 and 11β-HSD-2 
[59]. This result highlights the potential for placental adaptations to obesity to have short 
and long-term implications for the neurocognitive development of offspring. Compared to 
their lean counterparts, obese pregnant women are more likely to have a low education 
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status, to reside in an area of socioeconomic deprivation, and are around 40% more likely to 
develop antenatal depression [60,61]. Further research into these exposures is therefore 
crucial to advance the health of obese pregnant women and their offspring across the 
generations.  
 
Placental nutrient transporters 
 
Glucose 
 
Glucose is the primary energy source for the fetus and placenta. The fetus produces minimal 
endogenous glucose and is therefore reliant on the transplacental supply from the maternal 
circulation. Glucose is transported, down its concentration gradient, by facilitated carrier-
mediated diffusion across glucose transport proteins (GLUTs) (Figure 3). GLUT1 is the 
primary placental isoform and is present on the MVM and BM of the syncytiotrophoblast 
[62]. It is present in abundance from early pregnancy and expression continues to increase 
until the late second trimester, remaining stable thereafter [63]. GLUT-1 is distributed more 
densely on the MVM than the BM, suggesting that BM transport may provide the rate-
limiting step for placental glucose transport [64]. The syncytiotrophoblast cells express a 
range of other GLUT isoforms including GLUT-3, GLUT-4, GLUT-8, GLUT-9 and GLUT-10 [65]. 
GLUT-3 and GLUT-4 are expressed most highly in the first trimester and are therefore 
thought to play a more important role in glucose transport in early pregnancy [66,67].   
 
The impact of obesity and infant birthweight on placental glucose transport was examined 
in a cohort of predominantly Hispanic, non-diabetic, overweight/obese women (n=32) and 
lean controls (n=20) [68]. Maternal BMI demonstrated a positive correlation with umbilical 
vein glucose, a surrogate marker of fetal serum glucose levels. Analysis of isolated BMs 
demonstrated that increasing birthweight was associated with increased protein expression 
of GLUT-1 (r2=0.14, p=0.03). However, birthweight did not correlate with glucose transport 
activity at the BM or MVM. There was no correlation between birthweight and expression 
of MVM GLUT-1, BM GLUT-9 or MVM GLUT-9. Increasing birthweight demonstrated a 
positive correlation with maternal BMI (r2=0.16, p=0.03), umbilical vein glucose (r2=0.24, 
p=0.008), umbilical vein insulin (r2=0.19, p=0.04) and placental weight (r2=0.34, p=0.001). 
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There was no association between maternal fasting glucose and umbilical vein glucose. 
These findings raise the possibility that heavier placentas from overweight and obese 
women possess a greater surface area to facilitate glucose transport, or that placenta 
glucose metabolism is decreased in this cohort, in either case resulting in greater glucose 
availability for the fetus. The correlation of birthweight and umbilical vein glucose and 
insulin levels supports the presence of fetal insulin resistance in babies born to overweight 
and obese mothers, findings replicated in another obese cohort [7].    
 
Colomiere et al investigated the effect of obesity on glucose transporters and insulin 
signalling molecules including insulin receptor substrate 1 and 2, PI3K 85α and PI3K 110 α 
[69]. PI3K (phosphatidylinositol-3-kinase) proteins are a family of heterodimeric enzymes 
with key roles in insulin signalling pathways, including the ability to regulate glucose 
transporter activity [69]. They consist of a p85 regulatory subunit and a p110 catalytic 
subunit [70]. Comparing lean and obese women with normal glucose tolerance (n=6 per 
group), a significant reduction in GLUT-4 mRNA in was observed in obese women. This was 
not associated with any difference in GLUT-4 protein expression. There was no difference in 
protein or mRNA expression for GLUT-1, insulin receptor β (IR-β) or insulin receptor 
substrate 1 between groups. An increase in insulin receptor substrate 2 protein expression 
and decrease in PI3K p85a mRNA and protein expression was noted in obese women 
compared to lean women. Whilst these findings suggest obesity is associated with 
alterations in post-receptor insulin signalling, reproduction of this finding further study in a 
larger sample would be valuable. 
 
A C57/BL6 mouse model of maternal obesity demonstrated significant increases in 
transplacental glucose transport [26]. Female mice, fed a high-fat or control diet for 8 weeks 
before mating and throughout pregnancy, were studied at embryonic day 18.5. Mean fetal 
weight at E18.5 was increased by 43% in the high fat diet group, with no difference 
observed in mean placental weight between groups. MVM GLUT-1 expression was increased 
5-fold in high fat diet mice compared to controls. Similarly, placental glucose transport 
quantified by in vivo studies using a [3H]methylglucose tracer, was increased 5-fold in the 
high fat diet group compared to controls. There was no difference in GLUT-3 expression, 
measured in total placental homogenate, between the two diet groups. BM GLUT 
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expression was not examined in this study. The finding of increased placental glucose 
transport and unchanged placental weight in obese mice compared to controls is in contrast 
to the results reported by Acosta et al [68], highlighting potential limitations of the murine 
model in modelling a chronic metabolic disease.    
 
Inflammation and glucose transport 
 
During pregnancy, obese women demonstrate elevated plasma levels of pro-inflammatory 
mediators and enhanced immune cell infiltration in the placenta [23,71]. It is hypothesised 
that a pro-inflammatory in utero environment alters placental glucose transport in the 
context of obesity. The pro-inflammatory cytokine hepatocyte growth factor is expressed 
strongly in the placental syncytiotrophoblast, extravillous trophoblast and amniotic 
epithelium. Elevated serum hepatocyte growth factor levels have been reported in the non-
pregnant obese population, partly attributed to elevated synthesis within the adipose 
tissue. [72,73]. Through its action binding to the transmembrane c-met receptor, 
hepatocyte growth factor has numerous growth-promoting functions including regulation of 
glucose and lipid metabolism in pancreatic beta cells, adipocytes and skeletal muscle cells 
[74]. Levels of total and activated- hepatocyte growth factor, quantified by enzyme-linked 
immunosorbent assay, were significantly increased in the amniotic fluid of obese women 
(n=12; approximately 30ng/mL) compared to lean women (n=29, approximately 24 ng/mL) 
[75]. Western blot analysis revealed a 3-fold increase in hepatocyte growth factor protein 
levels in the placental tissue of obese compared to lean women. The role of hepatocyte 
growth factor in glucose transport was examined using placental explants preincubated in 
the presence or absence of hepatocyte growth factor. Uptake of 2-deoxyglucose was 
significantly increased in the presence of hepatocyte growth factor with a maximal 
increment of 30% noted at the 30ng/mL concentration. This was accompanied by an 
approximate 20% increase in glycolysis within the explants. Further Western blot analysis of 
placental explant samples from control participants (n=4) revealed incubation in 30ng/mL 
hepatocyte growth factor for 18 hours was associated with a 25% increase in GLUT-1 
expression. The impact of hepatocyte growth factor on placental glucose uptake was 
abolished completely by inactivation of the PI3K pathway with wortmannin (a PI3K pathway 
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inhibitor) suggesting this pathway is involved in downstream signalling following c-met 
activation by hepatocyte growth factor.  
 
Another pro-inflammatory cytokine, resistin, is elevated in the serum of non-pregnant 
obese people and is associated with insulin resistance  [76]. Serum levels also increase in the 
third trimester of pregnancy, a trend thought to relate, at least in part, to increased 
trophoblast resistin production [77]. In vitro studies using normal cytotrophoblast cells and 
BeWo choriocarcinoma cells (a cell line commonly used to model the first trimester 
trophoblast) found exposure to recombinant resistin was associated with increased glucose 
uptake, GLUT-1 messenger ribonucleic acid expression and protein expression in both cell 
types [78]. Extracellular signal-regulated kinase 1 and 2 protein phosphorylation was 
highlighted as a potential mechanism through which resistin modifies placental GLUT-1 
expression.  The importance of inflammatory cytokines including hepatocyte growth factor 
and resistin in modulation of glucose transport in vivo during obese pregnancy requires 
further study.  
 
Fatty acids 
 
Fatty acids are vital macronutrients in fetal development required as an energy source, a 
structural component of cell membranes, tissues and organs, and as a precursor to many 
essential bioactive compounds. Fatty acids taken up by the placenta originate from two 
main sources in the maternal circulation: esterified fatty acids in triglycerides and 
nonesterified fatty acids. Fatty acids in triglycerides are broken down by hydrolysis into 
nonesterified fatty acids to facilitate transport across the placental syncytium (Figure 3). 
This process is catalysed by lipases such as lipoprotein lipase and endothelial lipase in the 
MVM [65]. Lipoprotein lipase preferentially hydrolyses triglycerides in chylomicrons and 
very low-density lipoproteins, whilst endothelial lipase typically hydrolyses high density 
lipoproteins and phospholipids [65]. Free fatty acids are transported across the 
syncytiotrophoblast MVM by transport proteins including fatty acid transport proteins 
(FATP), fatty acid translocase (FAT/CD36) and plasma membrane fatty acid binding protein 
(FABPpm) [79]. Once inside the cell, free fatty acids bind to fatty acid binding proteins 
where they may be beta-oxidised to produce energy, esterified for use as structural 
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components, or transferred through FATPs or FAT/CD36 in the BM and released into the 
fetal circulation [79]. FATPs are integral membrane proteins with a key role in long-chained 
fatty acid uptake. There are six members of the FATP family, five of which are present in the 
human placenta (FATP1-4 and FATP6; encoded by SLC27A1-4 and 6).  
 
Obesity may influence fatty acid transport in several ways leading to alterations in fetal 
development and growth trajectories. Placental samples obtained at term from lean (n=34) 
and obese (n=55) women showed placentas from obese pregnancies contained a higher 
triglyceride content [80]. Obesity was associated with increased expression of six genes 
related to lipid transport and storage including FATP1, FATP3, adipose triglyceride lipase (a 
lipase localized in the syncytiotrophoblast) and CGI-58 (comparative gene identification-58; 
a regulator of hydrolysis) (p<0.05). In a ewe model of obesity at mid gestation (day 75), 
placental mRNA expression of FATP-1 and FAT/CD36 were significantly increased compared 
to normal controls (p<0.05), alongside protein expression of FATP-1 and FATP-4 (p<0.05) 
[81]. An increase in FATP-4 mRNA expression was also noted which trended towards 
significance (p=0.08). Similar findings were noted near term (day 135) with mRNA 
expression of FATP-1, FATP-4 and FAT/CD36 all increased in the obese group (p<0.05), 
although only FATP-4 protein expression was higher in this group (p<0.05). No difference in 
lipoprotein lipase mRNA expression was noted between groups at either gestation. 
Interestingly, fetuses of obese ewes were significantly heavier than fetuses of control ewes 
on day 75 (185.7± 6.89 vs 234.4±6.61g), but this difference did not persist at day 150 (5.05 ± 
0.28 vs 5.02 ± 0.25kg). The same pattern was also described in the placental weight 
between groups. Whilst the reason for these observations are unknown, this presents an 
interesting model for further study to enhance the understanding of placental development 
and function in the context of obesity. Placental endothelial lipase activity did not appear to 
differ comparing term placental samples from obese (n=170) and lean (n=71) women [82]. 
This was in contrast to placental samples from obese women with gestational diabetes 
mellitus (n=26), where expression was increased 1.9-fold (p<0.05) [82]. 
 
The potential of the pro-inflammatory obesogenic environment to influence fatty acid 
metabolism  was examined in a cohort of lean (n=7) and overweight/obese (n=5) women 
[83]. IL-6, but not tumour necrosis factor-α (TNF-α), was found to stimulate fatty acid 
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accumulation in primary cultured trophoblast cells from lean, overweight and obese 
women. No changes were noted in expression of FATP, lipoprotein lipase, or other 
examined markers, therefore the mechanism of this association is unclear.  
 
Amino acids 
 
Amino acids are vital substrates for the fetal production of nucleic acids and proteins, 
facilitate fetal growth and stimulate insulin release from the fetal pancreas [84]. Placental 
amino acid transport occurs against its concentration gradient across the 
syncytiotrophoblast, with intervillous blood amino acid concentrations generally more than 
two-fold greater than maternal concentrations [85]. Transport by active transport through 
accumulative transporters and exchangers on the MVM and BM (Figure 3). Accumulative 
transporters generally increase intracellular concentrations of amino acids by mediating 
uptake often by co-transporting extracellular sodium [86]. Exchangers alter amino acid 
concentrations by swapping amino acids between intracellular and extracellular 
compartments. Placental amino acid transport is tightly regulated with more than 20 known 
amino acid transporters. These include seven neutral amino acid transporters, including 
system A and system L. These systems are distinct in their substrate specificity and sodium 
dependency [87]. The role of amino acid transport activity in modulating fetal growth in 
obesity has been demonstrated in studies investigating various regulatory pathways.    
 
The hormone leptin, produced by adipocytes and placenta, is a key regulator of appetite 
and is present in elevated concentrations in obesity [88]. In term primary villous fragments 
obtained from uncomplicated, normal-weight pregnancies, leptin was shown to stimulate 
placental system A transport activity through phosphorylation of  STAT3 (a transcription 
factor) and activation of the JAK-STAT signalling pathway [89]. In a study of obese (n=7) and 
lean (n=7) pregnant women, obesity was associated with decreased placental system A 
sodium-dependent neutral amino acid transporter (SNAT) activity (p=0.005), maternal 
hyperleptinemia (p=0.01) and decreased syncytiotrophoblast expression of leptin receptor 
(p=0.01) and SNAT-4 (p<0.001) [90]. In addition, placental amino acid uptake was 
significantly stimulated by leptin in the lean women compared to the obese women. These 
findings were despite similar gestational weight gain and birthweights between groups. In 
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contrast, no significant difference in system L activity was identified comparing primary 
human trophoblast cells from overweight/obese (n=24) and lean (n=20) women [91].   
 
The mammalian target of rapamycin (mTOR) pathway is thought to be a principal regulator 
of placental amino acid transport [92]. Activity of mTOR signalling was assessed alongside 
other key signalling pathways, including insulin/insulin-like growth factor-1, in term 
placental samples from 16 healthy pregnant women across a range of BMI [25]. BMI was 
found to negatively correlate with activity of AMPK, which inhibits mTOR, positively 
correlate with insulin/insulin-like growth factor-1 signalling, which stimulates mTOR. mTOR 
activity was also found to positively correlate with increasing birthweight (p<0.001).  In this 
cohort, SNAT-1 and SNAT-4 expression were not significantly correlated to birthweight or 
maternal BMI. However, SNAT-2 expression was positively correlated with maternal early 
pregnancy BMI (p<0.05) and birthweight (p<0.01). On the contrary, placental mTOR gene 
expression was reduced in Spanish cohort of obese women (n=21) compared to lean women 
[93]. Gene expression of an upstream mTOR regulator (Akt1) and a downstream regulator 
(p70S6KB1) were unchanged. Interestingly these findings differed from obese women with 
gestational diabetes mellitus (n=11), who demonstrated increased mRNA expression of 
p70S6KB1.  
 
Oleic acid, a nonesterified fatty acid, comprises 30% of circulating nonesterified fatty acids 
during pregnancy [94]. In cultured human trophoblast cells from term placentas obtained 
from lean, overweight and obese pregnancies, exposure to oleic acid doubled system A 
activity (p<0.05), increased STAT3 phosphorylation (p<0.05), but had no effect on system L 
or mTOR activity. Obese pregnant women have elevated plasma fatty acid levels therefore 
these findings reveal a novel potential mechanism through which maternal obesity is 
associated with increased amino acid transport and subsequent fetal growth.  
 
Studies in a rat model of intra-uterine growth restriction using a low protein diet reported 
that down-regulation of amino acid transport predated the onset of intra-uterine growth 
restriction, rather than occurring as an adaptive response to growth restriction. Whilst the 
temporal nature of altered amino acid transport has yet to be determined in the context of 
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maternal obesity, this finding raises the possibility that up-regulation of amino acid 
transport may have a role in precipitating fetal overgrowth [95]. 
 
Epigenetics and maternal obesity 
 
During prenatal development, cells and tissues acquire different patterns of gene expression 
in the absence of changes to the DNA sequence. These stable but reversible alterations, 
known as epigenetic modifications or marks, include DNA methylation, histone 
posttranslational modifications and non-coding RNAs [16]. Crucial timepoints for epigenetic 
programming during development include gametogenesis, as primordial germ cells 
differentiate into mature sperm and oocytes, following fertilisation and during pre-
implantation development [96]. DNA methylation, which primarily occurs at cytosines in 
cytosine-guanine (CgP) dinucleotides, is the most widely studied epigenetic process [97]. As 
epigenetic modifications may be transmitted through generations of cell divisions, 
epigenetics has received great attention as a potential causal mechanism through which 
environmental exposures during early development mediate their effect on the long-term 
health of the offspring. Human studies examining the relationship between maternal 
obesity and DNA methylation changes in placenta, umbilical cord and cord blood of 
offspring are summarised in a 2017 review by Godfrey et al [16]. The following studies are of 
particular relevance to epigenetic changes in the placenta of obese women.   
 
Michels et al. studied the association between maternal BMI and methylation of Long 
Interspersed Nuclear Elements (LINE) 1 (LINE-1) [98]. Approximately 50% of the human 
genome is composed of repetitive sequences including LINE and Short Interspersed Nuclear 
Elements (SINE). LINE-1 methylation decreases with advancing age, and hypomethylation 
has been associated with cancers and implicated as a poor prognostic indicator in the 
oncology setting [98]. In placental samples from 316 mother-child dyads, no association was 
found between maternal pre-pregnancy BMI, gestational weight gain or 
birthweight/placental weight ratio with LINE-1 methylation. The only significant result in 
placental sample analysis was an association between low birthweight (<2500g, 29 dyads) 
and a 1.41% increase in LINE-1 methylation, compared to infants of normal birthweight 
(95% CI 0.18-2.63, p=0.025). This association was strengthened in a sub-group analysis of 
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term infants, with a difference of 2.6% methylation compared to normal birthweight infants 
(p=0.0014). Interestingly, associations with reduced LINE-1 methylation were noted in the 
umbilical cord blood samples of low birthweight babies (-0.82%, 95% CI -1.42 to –0.23, 
p=0.007) and also macrosomic babies (62 dyads; -0.43%, 95% CI -0.84 to -0.03, p=0.036).  
 
A comparison of the pattern of genome-wide DNA methylation and hydroxymethylation, 
known as the ‘methylome’, was performed by Mitsuya and colleagues using placental 
samples from obese and normal weight pregnancies (n=10 placentas combined in each 
group) [99]. Samples were obtained after delivery by elective caesarean section at term in 
the absence of labour, from women with no medical co-morbidities. Differences in 
methylated and hydroxymethylated regions were identified in a widespread pattern across 
the genome with a 21% increase in the number of methylated regions and 31% decrease in 
the number of hydroxymethylated regions in the obese compared to lean group. Changes 
were identified in diverse sites across the genome including around transcription start sites, 
CpG rich areas (CpG islands) and regions adjacent to CpG rich areas (CpG shores and 
shelves). Regions with differential methylation and hydroxymethylation patterns (i.e. 
increased methylation and decreased hydroxymethylation) were identified around 
transcription start sites of multiple genes in two pregnancy-associated gene clusters: the 
growth hormone-chorionic somatomammotropin hormone cluster on chromosome 17q24 
and pregnancy-specific glycoprotein gene cluster on chromosomes 19q13. The growth 
hormone-chorionic somatomammotropin hormone encodes hormones vital for fetal 
growth, metabolism and stimulation of lactation whilst pregnancy-specific glycoprotein is 
thought to have a vital immune-modulating function [99,100]. Increased methylation was 
only associated with decreased mRNA expression of some genes in these clusters, 
suggesting further research into the clinical significance of these findings is required.   
 
A second genome-wide study of the methylome in maternal obesity, performed in a multi-
ethnic cohort, found global methylation levels were higher in placental samples from obese 
women (n=18, 56.1%) compared to lean women (n=32, 53.64%, p=0.01) [101]. This finding 
remained significant in a model adjusted for patient demographics (p=0.01). There was no 
difference in methylation noted between obese and lean groups on analysis of umbilical 
cord blood samples. Of note, these analyses did not control for concomitant medical 
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diagnoses of pre-eclampsia or gestational diabetes in adjusted analyses. There was also no 
association demonstrated between global methylation (in placenta and umbilical cord 
blood) with birth outcomes including birth weight and gestational age at birth.  
 
A murine model was used to evaluate the impact of maternal obesity and pre-conception 
weight loss on the expression of epigenetic genes in two distinct placental zones: the 
placental labyrinth, known as the fetal placenta in humans, and the junctional zone, 
referred to as the basal plate or implantation site in humans [102,103]. For four months 
prior to conception, female mice were fed a control diet, a high fat diet, or a weight loss diet 
(high fat for two months followed by control diet for two months). This model of obesity 
was associated with fetal growth restriction in the offspring (an expected pattern in the 
murine model), which was partially restored in the weight loss group. Expression of 60 
‘epigenetic machinery’ genes implicated in metabolic diseases including obesity and type 2 
diabetes, and 32 genes involved in developmental conditioning, were examined using low 
density arrays. By hierarchical cluster analysis, the obese group demonstrated a change in 
mean expression of the 86 analysed genes in the labyrinth zone, compared to the control 
and weight loss groups. This finding was not replicated in the junctional zone. Maternal 
obesity was associated with altered expression of nine epigenetic genes in the labyrinth 
zone compared to the control group including downregulation of histone acetylation 
enzymes, 11βHSD1 and insulin receptor substrate 1. In the weight loss group, several genes 
were down-regulated in a similar pattern to the obese group, however others were 
measured at levels similar to the control group. In the junctional zone, one histone 
acetylation enzyme (Kat3b) was upregulated in the weight loss group compared to control, 
with no investigated genes affected in the obese group. These findings may be of relevance 
to histone acetylation pathways in the human fetal placenta and highlight the potential for 
distinct epigenetic patterns to affect varying placental sites.     
 
Finally, methylation of the GR gene promoter region 1F in placental samples was shown to 
associate with birthweight category in a study involving 480 participants [104]. After 
Bonferroni correction for multiple comparisons, only one CpG site (out of thirteen) and the 
mean across all CpG sites showed a significantly difference, with increased methylation in 
the large for gestational age group (>90th percentile of weight for gestational age, n=35) 
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compared to the appropriate and small for gestational age groups (n=343 and n=102 
respectively). Adjusted analyses revealed birthweight was significantly correlated with mean 
GR methylation extent (r=0.16, p=0.0004). Unfortunately, data on maternal BMI or weight 
was not available in this cohort. Altered methylation of the GR may lead to dysregulation of 
offspring glucocorticoid homeostasis, and potentially contribute to the development of 
metabolic disease including type 2 diabetes and obesity. For these reasons, further 
investigation into GR methylation and other epigenetic marks in the context of maternal 
obesity would be valuable. 
 
Despite the potential for epigenetic studies to provide major breakthroughs into our 
understanding of developmental programming, it is important to acknowledge their 
limitations. Firstly, the clinical significance of the epigenetic markings discussed in this 
section is unknown. The magnitude of the role, if any, these changes have in contributing to 
the adverse phenotypes experienced in later life by the offspring of obese women remains 
to be elucidated [16]. Indeed, it is unknown if these changes occur in response to the 
obesogenic intra-uterine environment to aid fetal adaptation, or if they are simply a 
downstream consequence of changes in fetal growth which occur in the context of obesity. 
It has also been speculated that term placental samples reflect an organ at the end of its life 
cycle, and therefore a declining metabolic rate may be reflected in results relating to 
epigenome activity [98].  Finally, the placenta is known to consist of different cell 
populations, each which has the potential to exhibit a unique epigenetic pattern [16]. This 
adds a further layer of complexity in interpreting the results of mechanistic studies. At 
present there are no longitudinal studies following-up the impact of epigenetic changes 
observed at birth in the offspring of obese women on health in later life. Whilst this would 
provide invaluable insight into the role of epigenetics in developmental programming, it 
would also be practically challenging to perform.  
 
Conclusion 
 
The placenta is developmentally plastic and adapts to the maternal environment in order to 
optimise fetal growth and development. In the setting of maternal obesity, the placenta 
must function despite a milieu of inflammatory and metabolic disturbances. The findings 
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discussed in this review highlight the complexity of cellular pathways which may be altered, 
at least in part, by the obesogenic environment. Maternal obesity blunts the HPA axis 
activation associated with pregnancy, however the impact of obesity on placental 
glucocorticoid metabolism has yet to be determined. In particular, the impact of gestation 
and obesity on glucocorticoid sensitivity and ABC transporters presents a major knowledge 
gap. Maternal obesity is associated with excessive macronutrient exposure precipitating 
excess fetal growth. Despite detailed knowledge of the relevant placental transport 
mechanisms, further research is required to elucidate the mechanisms regulating these 
transporters, and the impact of obesity in this process. Furthermore, whilst differences in 
the epigenetic profile, specifically DNA methylation, of placentas from obese and lean 
women have been identified, the clinical implications of these findings are unknown. More 
detailed understanding in these fields may provide an opportunity to develop targeted 
novel interventions to offset the impact of obesity on the developing fetus, and potentially 
benefit the ever-growing numbers of offspring who are adversely impacted by their prenatal 
environment.  
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Figure 1. Schematic diagram representing the transport and metabolism of glucocorticoids 
in the fetal, syncytiotrophoblast and maternal compartments during pregnancy.  
 
Legend: Cortisol and corticosterone are metabolised to their inactive metabolites (cortisone 
and 11-dehydrocorticosterone) by the enzyme 11β-HSD-2 in the syncytiotrophoblast. 
Some of these inactive glucocorticoids are re-activated by 11β-HSD-1 in the fetal and 
maternal compartments. Cortisol is effluxed from the syncytiotrophoblast to the 
maternal circulation, whilst corticosterone is effluxed to the fetal compartment. 
ABCG2 is expressed on the microvillous membrane. The role of placental ABC 
transporters in glucocorticoid transport has yet to be fully established. 
Mineralocorticoid receptors are expressed in the syncytiotrophoblast, maternal and 
fetal compartments (not depicted).  
 
Figure 2: 11β-HSD-2 staining in the syncytiotrophoblast of term placental tissue from a 
normal weight woman. 
Legend: Immunohistochemistry staining for 11β-HSD-2 protein (brown) with nuclear 
counterstaining (blue) in term trophoblast tissue collected from a normal weight woman, A: 
50x magnification, B: 400x magnification of placental villi. 
 
Figure 3: Schematic diagram representing the transport of glucose, amino acids and fatty 
acids from the maternal to the fetal circulation across the syncytiotrophoblast. 
 
Legend: Maternal blood in the intervillous space of the placenta bathes the microvillous 
membrane. Glucose transport proteins, amino acid transporters and fatty acid transporters 
are present on both sides of the syncytiotrophoblast, allowing movement of macronutrients 
across the syncytiotrophoblast from the maternal to the fetal circulation. Lipoproteins 
containing fatty acids, for example triglycerides, are cleaved by lipases attached to the 
microvillous membrane (MVM), resulting in the release of free fatty acids (FFAs). FFAs are 
transported across the MVM by fatty acid transporters, then bound to fatty acid binding 
proteins (FABP) within the cytosol of the syncytiotrophoblast which guide further transport. 
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MVM: microvillous membrane, BM: basal membrane, GLUT: glucose transport protein, AA: 
amino acid, TG: triglyceride, LPL: lipoprotein lipase, EL: endothelial lipase, FFA: free fatty 
acids, FABPpm: plasma membrane fatty acid binding protein, FATP: fatty acid transport 
protein, FAT/CD36: fatty acid translocase. 
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